Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)
China
· Delayed Price · Currency is CNY 35.92
+1.59 (4.63%)
Apr 29, 2026, 3:00 PM CST
Hangzhou Biotest Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Net Income | 28.19 | 47.13 | 169.52 | 106.61 | 773.63 | 833.59 | Upgrade
|
| Depreciation & Amortization | 24.27 | 24.27 | 22.62 | 29.17 | 23.25 | 10.53 | Upgrade
|
| Other Amortization | - | - | 0.11 | 0.1 | 0.08 | 0.1 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.25 | -0.25 | 0.33 | -0 | - | 0 | Upgrade
|
| Asset Writedown & Restructuring Costs | 5.48 | 5.48 | - | 6.35 | 18.78 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -3.97 | -3.97 | -7.05 | -3.38 | -14.85 | -1.07 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 3.52 | 3.67 | -5.59 | 3.21 | Upgrade
|
| Other Operating Activities | -13.88 | 12.74 | 11.05 | 36.27 | -48.37 | 29.38 | Upgrade
|
| Change in Accounts Receivable | 3.79 | 3.79 | -39.78 | -13.57 | 107.84 | -51.4 | Upgrade
|
| Change in Inventory | -2.04 | -2.04 | 3.13 | -14.14 | -48.93 | -60.84 | Upgrade
|
| Change in Accounts Payable | 8.84 | 8.84 | -43.09 | -20.43 | -98.94 | 145.05 | Upgrade
|
| Change in Other Net Operating Assets | 8.78 | 8.78 | 6.53 | 2.46 | 5.31 | 1.05 | Upgrade
|
| Operating Cash Flow | 60.91 | 106.47 | 128.83 | 131.38 | 703.21 | 908.12 | Upgrade
|
| Operating Cash Flow Growth | -39.02% | -17.36% | -1.94% | -81.32% | -22.56% | 103.58% | Upgrade
|
| Capital Expenditures | -142.44 | -129.87 | -245.05 | -56.42 | -178.92 | -200.2 | Upgrade
|
| Sale of Property, Plant & Equipment | 2.74 | 2.74 | 0.08 | 0.18 | - | - | Upgrade
|
| Investment in Securities | -332.98 | 251.83 | -601.82 | 126.76 | 260.84 | -400 | Upgrade
|
| Other Investing Activities | 5.57 | 7 | 8.54 | 3.84 | 14.79 | 0.23 | Upgrade
|
| Investing Cash Flow | -467.11 | 131.7 | -838.25 | 74.36 | 96.71 | -599.97 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 0.24 | - | 5.56 | Upgrade
|
| Total Debt Issued | - | - | - | 0.24 | - | 5.56 | Upgrade
|
| Short-Term Debt Repaid | - | - | -0.15 | - | -5.29 | -11 | Upgrade
|
| Long-Term Debt Repaid | - | - | -2.45 | -4.17 | -2.8 | -2.46 | Upgrade
|
| Total Debt Repaid | - | - | -2.6 | -4.17 | -8.08 | -13.46 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | -2.6 | -3.93 | -8.08 | -7.9 | Upgrade
|
| Issuance of Common Stock | - | - | 24.87 | 4.17 | - | 856.14 | Upgrade
|
| Repurchase of Common Stock | - | - | -43.18 | -14.76 | - | - | Upgrade
|
| Common Dividends Paid | -106.67 | -159.88 | -83.65 | -234.67 | -320.01 | -20.91 | Upgrade
|
| Other Financing Activities | 4.46 | 1.82 | - | - | -4.56 | -14.09 | Upgrade
|
| Financing Cash Flow | -102.21 | -158.06 | -104.55 | -249.19 | -332.65 | 813.24 | Upgrade
|
| Foreign Exchange Rate Adjustments | -29.79 | -12.68 | 10.5 | 10.89 | 104.91 | -14.82 | Upgrade
|
| Net Cash Flow | -538.2 | 67.44 | -803.48 | -32.55 | 572.18 | 1,107 | Upgrade
|
| Free Cash Flow | -81.53 | -23.4 | -116.23 | 74.96 | 524.29 | 707.92 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -85.70% | -25.94% | 82.27% | Upgrade
|
| Free Cash Flow Margin | -18.14% | -5.22% | -20.78% | 16.95% | 27.58% | 38.94% | Upgrade
|
| Free Cash Flow Per Share | -0.56 | -0.16 | -0.79 | 0.50 | 3.51 | 5.84 | Upgrade
|
| Cash Income Tax Paid | - | -30.31 | -0.27 | 3.48 | 143.63 | 67.92 | Upgrade
|
| Levered Free Cash Flow | -76.01 | -49.24 | -173.95 | -18 | 279.64 | 443.47 | Upgrade
|
| Unlevered Free Cash Flow | -76.01 | -49.24 | -173.93 | -17.91 | 279.77 | 443.89 | Upgrade
|
| Change in Working Capital | 21.06 | 21.06 | -71.28 | -47.41 | -43.71 | 32.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.